AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02930655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
Study NCT02930655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Description: All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
Study NCT03960138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-burst stimulation (iTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
Study NCT03960138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst stimulation (cTBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
Study NCT03599141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-building Self-management Together
Description: Trust building plus depression self-management
Study NCT03599141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression Management
Description: Traditional depression self-management
Study NCT02274584 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR T cells
Description: Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
Study NCT03016442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Double Balloon Catheter
Description: A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
Study NCT03016442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: 10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Study NCT02226042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00634244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT02636348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: 2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
Study NCT02636348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily as 8 placebo pills or 2 unfortified snack bars.
Study NCT00465153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flax oil containing alpha linolenic acid
Description: 14g alpha linolenic acid per day
Study NCT00465153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: flax oil containing alpha linolenic acid
Description: 14g alpha linolenic acid per day
Study NCT00465153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Resistance training
Study NCT04491786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin plus nefopam
Study NCT00466999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: single dose of 400 mcg misoprostol administered sublingually
Study NCT03223675 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampal-sparing WBRT
Study NCT04438824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
Study NCT04438824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
Study NCT04587492 — intervention group
Intervention type: DRUG
Intervention: Nusinersen
Description: Treatment with nusinersen
Study NCT04063202 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
Study NCT04053387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapinarof cream, 1%
Description: Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
Study NCT00694863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracosactide hexacetaat
Description: Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
Study NCT00466999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: standard surgical treatment (dilation and curettage or manual vacuum aspiration)
Study NCT01721408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
Study NCT01721408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
Study NCT04065880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil®
Description: topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
Study NCT04065880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoveil®
Description: bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
Study NCT02510729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation
Study NCT02510729 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Study NCT04565249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809
Study NCT04565249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04813393 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Development
Description: To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
Study NCT02271048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ultrasonography interpretation using the smartphone
Description: The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
Study NCT00633412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg oral daily
Study NCT00633412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150mg oral twice daily
Study NCT00633412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral tablet daily
Study NCT01061229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic drug C12
Description: Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
Study NCT01061229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
Study NCT06630481 — intervention group
Intervention type: DRUG
Intervention: neoadjuvant therapy
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
Study NCT02333630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AsthmaCare mobile health application
Description: Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
Study NCT02333630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education
Description: A website with links to written asthma education and videos
Study NCT04417270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Freestyle Libre 14 day CGM system
Description: The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
Study NCT04417270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accuchek Inform II platform
Description: The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
Study NCT02380742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine cream
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
Study NCT02380742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
Study NCT02689349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Esteem
Description: Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
Study NCT02689349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of Esteem
Description: Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
Study NCT00324506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (CellCept)
Study NCT04471467 — intervention group
Intervention type: PROCEDURE
Intervention: Fixed tracheal tube
Description: Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
Study NCT00719017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper vaginectomy
Description: Laparoscopic surgery with upper vaginectomy
Study NCT00719017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative brachytherapy
Description: Laparoscopic surgery followed by brachytherapy
Study NCT00719017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard procedures
Description: Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
Study NCT03675139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate
Description: At a dosage of 10mg/day
Study NCT03675139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG
Description: At a dosage of 20 mg/day
Study NCT05122312 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olinanoseal
Description: it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
Study NCT05122312 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Curodont D'senz
Description: This agent contains p 11-4 peptide in addition to fluoride
Study NCT00530335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
Study NCT03213405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV 1/100
Description: 5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
Study NCT03213405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV 1/10
Description: 5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
Study NCT03213405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV full dose
Description: 1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
Study NCT03213405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional BCG full dose
Description: 2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
Study NCT01073293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 Vaccine
Description: V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
Study NCT01073293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX™ (Concomitant)
Description: REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
Study NCT01073293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX™ (Non-concomitant)
Description: REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
Study NCT03910595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Description: Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
Study NCT01514357 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nesiritide (BNP)
Description: NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
Study NCT01514357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
Study NCT02966743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: administration of midazolam during spinal anesthesia for target bispectral index 75-80
Study NCT02966743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
Study NCT02137343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
Study NCT02714127 — intervention group
Intervention type: OTHER
Intervention: First-void urine collection
Description: One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
Study NCT02137343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02137343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
Study NCT02137343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
Study NCT02137343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Study NCT02137343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Study NCT04023045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assist-Knee
Description: Assist-Knee is an experimental lower limb knee prosthesis.
Study NCT04023045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Prosthesis
Description: Habitual baseline prosthesis prescribed by participant's clinician.
Study NCT02500108 — intervention group
Intervention type: DRUG
Intervention: Domperidone
Description: Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date).
Study NCT02314923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Vaccine
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
Study NCT02314923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline
Study NCT01651208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)
Description: We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment.